Evidence map›Paper›PMID 36313779›Full record

ArticleFrontiers in endocrinology2022

Investigation of anti-diabetic potential and molecular simulation studies of dihydropyrimidinone derivatives.

Umair Ilyas, Bisma Nazir, Reem Altaf, Syed Aun Muhammad, Hajra Zafar, Ana Cláudia Paiva-Santos, Muhammad Abbas, Yongtao Duan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Umair IlyasHenan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, China.
Bisma NazirRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan.
Reem AltafDepartment of Pharmacy, Iqra University Islamabad Campus, Islamabad, Pakistan.
Syed Aun MuhammadInstitute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan.
Hajra ZafarSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Ana Cláudia Paiva-SantosDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.
Muhammad AbbasRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan.
Yongtao DuanHenan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, China.
Riphah International University · PKZhengzhou University · CNBahauddin Zakariya University · PKIqra University · PKRede de Química e Tecnologia · PTShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In an attempt to find new targets for α-amylase and α-glucosidase for the treatment of type 2 diabetes mellitus, the present study aims in determining the anti-diabetic potential of synthesized dihydropyrimidinone derivatives. The

Indexed as

alpha-GlucosidasesDiabetes Mellitus, Type 2alpha-AmylasesHumansLigandsMolecular Docking Simulationalpha-Amylasesalpha-GlucosidasesLigandsalpha-glucosidaseanti-diabeticDihydropyrimidinonesin-silicomolecular docking

Identifiers

PMID36313779
PMCPMC9596752
OpenAlexW4304786591

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.